Previous 10 | Next 10 |
home / stock / nktx / nktx articles
Nkarta, Inc. (NASDAQ: NKTX) posted a loss for the fourth quarter on Thursday. The company posted a quarterly loss of 57 cents per share, compared ...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered nat...
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Nkarta, Inc. (NASDAQ:NKTX) ...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 100 points on Tuesday. Shares of Hewlett Packard Enterprise ...
Nkarta, Inc. (NASDAQ: NKTX) shares are blasting higher Monday, and the stock has gained more than 270% over the past month. Here's a look at wh...
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 37...
Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guida...
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) sh...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Nkarta, Inc. (NASDAQ:NKTX) ("Nkarta") on beh...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sp...
SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing...